Himalaya Nutravedics India Ltd IPO
- Price band
- ₹100 to ₹106
- Issue size
- ₹26.5 Cr
- Issue price
- ₹106
- Lot size
- 1,200 shares
- Min. investment
- ₹2,54,400
- Listing return
- +11.32%
2,400 shares
Listed ₹118
Opens
22 Sep 2026
Closes
24 Sep 2026
Allotment
25 Sep 2026
Listing
29 Sep 2026
Subscription
About the company
Himalaya Nutravedics India Ltd makes, markets and distributes Ayurvedic and nutraceutical products in India, and also does contract manufacturing for other companies in the same space. Its range covers classical formulations drawn from recognised Ayurvedic texts, proprietary Ayurvedic products and nutraceutical supplements, offered as soft and hard gelatin capsules, tablets, liquid orals and medicated oils; the nutraceuticals use vitamins, minerals, herbal extracts, amino acids and other permitted ingredients. The company runs both its own brands and third-party manufacturing. Production began in September 2022 at its Cherlapally, Hyderabad (Telangana) plant. Distribution is stockist-led across several states, backed by a field sales and marketing team of roughly 56 people, including regional managers and medical representatives.
Objective of IPO proceeds
| Particulars | Estimated amount (₹ Cr.) |
|---|---|
| Funding Working Capital Requirements | 13.75 |
| Investment in Branding, Digital Marketing and Sales Expansion | 7.5 |
| General corporate purposes. | — |
Key performance indicators (KPIs)
for the year ended March 31, 2026
- ROE63.87%
- ROCE36.41%
- EBITDA Margin18.82%
- PAT Margin17.16%
- Return on Net Worth (RoNW)45.12%
Debt-to-equity Ratio
0.31
Net Asset Value (NAV) per Equity Share
26.7
Price to Book Value
3.97
EPS (Pre IPO)
11.72
View table
| KPI | Value (for the year ended March 31, 2026) |
|---|---|
| ROE (%) | 63.87 |
| ROCE (%) | 36.41 |
| EBITDA Margin (%) | 18.82 |
| PAT Margin (%) | 17.16 |
| Debt-to-equity Ratio | 0.31 |
| Return on Net Worth (RoNW) (%) | 45.12 |
| Net Asset Value (NAV) per Equity Share (₹) | 26.7 |
| Price to Book Value | 3.97 |
| EPS (Pre IPO) (₹) | 11.72 |
Financials
₹ croreRevenue
43.07
Total Assets
24.42
Profit
7.39
View table
| Line | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 14.42 | 21 | 43.07 |
| Total Assets | 6.09 | 10.82 | 24.42 |
| Profit | 0.43 | 2.23 | 7.39 |
Book running lead managers & registrar
| Book running lead managers | Nirbhay Capital Services Private Limited |
|---|---|
| Registrar to the issue | KFin Technologies Limited |
| Market maker to the issue | Allwin Securities Limited |
Himalaya Nutravedics India IPO contact details
| Company name | Himalaya Nutravedics India |
|---|---|
| Registered office | Plot No. 101/A, Phase-III, Industrial Development Park, Cherlapally, Hindustan Cables Ltd, Uppal, Hyderabad – 500051, Telangana, India. |
| Phone | +91-9063498493 |
| info@himalayanutravedics.com | |
| Website | www.himalayanutravedics.com |
Himalaya Nutravedics India IPO registrar contact details
| Company name | KFin Technologies Limited |
|---|---|
| Phone | +91 40671 62222 / 1800 3094001 |
| himalaya.ipo@kfintech.com | |
| Website | www.kfintech.com/ |
Thesis
- 1
One integrated plant lets the company turn out medicated oils, soft and hard gelatin capsules, tablets and liquid orals, so it can cover many dosage forms for both its Ayurvedic and nutraceutical lines.
- 2
Its own-brand portfolio spans classical and proprietary Ayurvedic formulations plus nutraceutical supplements, addressing areas such as gut health, cardiac and metabolic wellness, diabetes, pain, immunity, infertility and general wellness.
- 3
The business combines its own brands with contract manufacturing for other Ayurvedic and nutraceutical firms, giving it two revenue routes.
- 4
In FY26 the own-brand segment brought in about Rs 22.02 crore, or 51.14% of total revenue.
- 5
Revenue from operations has climbed each year, from Rs 14.42 crore in FY24 to Rs 21.00 crore in FY25 and Rs 43.07 crore in FY26, while PAT rose from Rs 0.43 crore to Rs 2.23 crore and then Rs 7.39 crore.
- 6
Since starting production in September 2022, it has spread across several states with a stockist-based distribution network and a field sales and marketing team.
- 7
Management says practitioners have repeated prescriptions and re-orders, with the company relying on scientific detailing, continuing medical education, medical camps and practitioner engagement instead of mass media advertising.
Application details
Individual investor
₹100 - ₹106 · from ₹2,00,000 onwards.
1,200sharesMin 2,400
Figures come from the company filing. This is not a recommendation.